title: Epigenetic inactivation implies independent functions for insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes.
abstract: OBJECTIVE
  To analyze epigenetic regulation of two related genes, insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) and IGFBPL1, and its significance as a determinant of clinical phenotypes in human breast cancer.
  
  
  METHODS
  We have investigated the expression and epigenetic regulation of IGFBP-rP1 and IGFBPL1 in human breast cancer cell lines and primary and metastatic carcinomas.
  
  
  RESULTS
  Expression of IGFBP-rP1 and IGFBPL1 is down-regulated in breast cancer cell lines. Aberrant methylation in the CpG islands of each gene correlates well with loss of expression at the mRNA level. Analysis of methylation in DNA isolated from human primary breast tumors showed that methylation in either gene was associated with a worse overall survival (OS; P=0.008) and disease-free survival (DFS) following surgery (P=0.04) and worse DFS following adjuvant chemotherapy (P=0.01). Methylation of IGFBP-rP1 alone was associated with a trend toward decreased OS (P=0.10) and decreased DFS (P=0.25). Methylation in IGFBPL1 was clearly associated with worse OS (P=0.001) and DFS (P<0.0001). Methylation in either IGFBP-rP1 or IGFBPL1 was significantly associated with nodal disease (P<0.001).
  
  
  CONCLUSIONS
  Expression of IGFBP-rP1 and IGFBPL1 is regulated by aberrant hypermethylation in breast cancer, implying that inactivation of these genes is involved in the pathogenesis of this malignancy. Analysis of methylation of these genes may have utility in prediction of clinical phenotypes, such as nodal disease and response to chemotherapy.
authors.affiliation: The Breakthrough Toby Robins Breast Cancer Research Centre at The Institute of Cancer Research, Mary-Jean Mitchell Green Building, Chester Beatty Laboratories, London, UK.
authors.forename: Paul
authors.initials: P
authors.lastname: Smith
authors.forename: Linda J
authors.initials: LJ
authors.lastname: Nicholson
authors.forename: Nelofer
authors.initials: N
authors.lastname: Syed
authors.forename: Annette
authors.initials: A
authors.lastname: Payne
authors.forename: Louise
authors.initials: L
authors.lastname: Hiller
authors.forename: Ornella
authors.initials: O
authors.lastname: Garrone
authors.forename: Marcella
authors.initials: M
authors.lastname: Occelli
authors.forename: Milena
authors.initials: M
authors.lastname: Gasco
authors.forename: Tim
authors.initials: T
authors.lastname: Crook
mesh_terms: D001483:Base Sequence; D001943:Breast Neoplasms / Q000235:genetics* / Q000517:prevention & control*; D045744:Cell Line, Tumor; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000235:genetics; D044127:Epigenesis, Genetic; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000235:genetics*; D018969:Insulin-Like Growth Factor Binding Proteins / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013447:Sulfites; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000235:genetics* / Q000502:physiology
chemical_list: D004273:DNA, Neoplasm; C501532:IGFBPL1 protein, human; D018970:Insulin-Like Growth Factor Binding Protein 1; D018969:Insulin-Like Growth Factor Binding Proteins; D013447:Sulfites; D025521:Tumor Suppressor Proteins; C042345:hydrogen sulfite